Literature DB >> 24838721

Pharmacophore reassignment for induction of the immunosurveillance cytokine TRAIL.

Nicholas T Jacob1, Jonathan W Lockner, Vladimir V Kravchenko, Kim D Janda.   

Abstract

Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is an immunosurveillance cytokine that kills cancer cells but demonstrates little toxicity against normal cells. While investigating the TRAIL-inducing imidazolinopyrimidinone TIC10, a misassignment of its active structure was uncovered. Syntheses of the two isomers, corresponding to the published and reassigned structures, are reported. The ability of each to induce TRAIL expression in macrophages was investigated and it was found that only the compound corresponding to the reassigned structure shows the originally reported activity; the compound corresponding to the published structure is inactive. Importantly, this structural reassignment has furnished a previously unknown antitumor pharmacophore.
© 2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  TIC10; TRAIL; cancer therapy; drug discovery; structure elucidation

Mesh:

Substances:

Year:  2014        PMID: 24838721     DOI: 10.1002/anie.201402133

Source DB:  PubMed          Journal:  Angew Chem Int Ed Engl        ISSN: 1433-7851            Impact factor:   15.336


  15 in total

1.  Post-HTS case report and structural alert: Promiscuous 4-aroyl-1,5-disubstituted-3-hydroxy-2H-pyrrol-2-one actives verified by ALARM NMR.

Authors:  Jayme L Dahlin; J Willem M Nissink; Subhashree Francis; Jessica M Strasser; Kristen John; Zhiguo Zhang; Michael A Walters
Journal:  Bioorg Med Chem Lett       Date:  2015-08-10       Impact factor: 2.823

Review 2.  Recent trends in the structural revision of natural products.

Authors:  Bhuwan Khatri Chhetri; Serge Lavoie; Anne Marie Sweeney-Jones; Julia Kubanek
Journal:  Nat Prod Rep       Date:  2018-06-20       Impact factor: 13.423

3.  Identification of more potent imipridones, a new class of anti-cancer agents.

Authors:  Andrew S Chi
Journal:  Cell Cycle       Date:  2017-07-27       Impact factor: 4.534

Review 4.  Mitigating risk in academic preclinical drug discovery.

Authors:  Jayme L Dahlin; James Inglese; Michael A Walters
Journal:  Nat Rev Drug Discov       Date:  2015-04       Impact factor: 84.694

Review 5.  Mechanisms of imipridones in targeting mitochondrial metabolism in cancer cells.

Authors:  Erin R Bonner; Sebastian M Waszak; Michael A Grotzer; Sabine Mueller; Javad Nazarian
Journal:  Neuro Oncol       Date:  2021-04-12       Impact factor: 12.300

6.  The angular structure of ONC201, a TRAIL pathway-inducing compound, determines its potent anti-cancer activity.

Authors:  Jessica Wagner; Christina Leah Kline; Richard S Pottorf; Bhaskara Rao Nallaganchu; Gary L Olson; David T Dicker; Joshua E Allen; Wafik S El-Deiry
Journal:  Oncotarget       Date:  2014-12-30

7.  TIC10/ONC201: a bend in the road to clinical development.

Authors:  Yoshimi Endo Greer; Stanley Lipkowitz
Journal:  Oncoscience       Date:  2015-02-20

8.  TIC10/ONC201 synergizes with Bcl-2/Bcl-xL inhibition in glioblastoma by suppression of Mcl-1 and its binding partners in vitro and in vivo.

Authors:  Georg Karpel-Massler; Maïmouna Bâ; Chang Shu; Marc-Eric Halatsch; Mike-Andrew Westhoff; Jeffrey N Bruce; Peter Canoll; Markus D Siegelin
Journal:  Oncotarget       Date:  2015-11-03

9.  Route exploration and synthesis of the reported pyridone-based PDI inhibitor STK076545.

Authors:  Eric Greve; Sergey V Lindeman; Christina Scartelli; Lin Lin; Robert Flaumenhaft; Chris Dockendorff
Journal:  Org Biomol Chem       Date:  2020-08-19       Impact factor: 3.876

10.  Experimental and Chemoinformatics Study of Tautomerism in a Database of Commercially Available Screening Samples.

Authors:  Laura Guasch; Waruna Yapamudiyansel; Megan L Peach; James A Kelley; Joseph J Barchi; Marc C Nicklaus
Journal:  J Chem Inf Model       Date:  2016-10-16       Impact factor: 4.956

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.